Objective:

To investigate whether rapidly resorbable gelatin microspheres (RGMs) can protect non-tumorous liver (NTL) by temporarily modulating arterial flow during Y-90 radioembolization.

Approach:

• Study design: SEGWAY (NCT06229080) was a prospective, single-arm phase II trial planned for 20 adults with liver cancer.
• Eligibility: Participants had Child–Pugh class A status and NTL volume of at least 50% of the Y-90 perfused liver volume; patients with vascular invasion or biliary–enteric anastomosis were excluded.
• Intervention and planning: Operators used RGMs to protect selected NTL territories during Y-90 delivery. Treatment planning used the partition model and MAA SPECT/CT; operators selected microsphere type, activity, and prescribed tumor dose.

Key Findings:

• The supplied context describes the trial rationale and methods but does not report clinical outcomes or quantitative dosimetric results.

Interpretation:

The study was designed to assess temporary RGM-mediated flow modulation and NTL protection during Y-90 radioembolization; efficacy cannot be determined from the provided context.

Limitations:

• The trial was single-arm and planned to enroll 20 patients.
• The provided context does not include results.
• Prescribed tumor dose and microsphere type were determined by operators, and no fixed tumor or NTL dose target was specified.

Sources:

• Article context provided by the user